[go: up one dir, main page]

PE64396A1 - Proteina accesoria del receptor de la interleucina 1 - Google Patents

Proteina accesoria del receptor de la interleucina 1

Info

Publication number
PE64396A1
PE64396A1 PE1996000031A PE00003196A PE64396A1 PE 64396 A1 PE64396 A1 PE 64396A1 PE 1996000031 A PE1996000031 A PE 1996000031A PE 00003196 A PE00003196 A PE 00003196A PE 64396 A1 PE64396 A1 PE 64396A1
Authority
PE
Peru
Prior art keywords
accessory protein
receptor
polynucleotide
same
mentioned
Prior art date
Application number
PE1996000031A
Other languages
English (en)
Inventor
Richard Anthony Chizzonite
Grace Wong Ju
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE64396A1 publication Critical patent/PE64396A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A: i) EL POLINUCLEOTIDO QUE COMPRENDE UNA SECUENCIA DE ADN SELECCIONADA DE: a) UN POLINUCLEOTIDO QUE TIENE LA SECUENCIA SEQ ID NO:1; b) UN POLINUCLEOTIDO QUE HIBRIDA CON EL ADN DE (a) EN CONDICIONES RESTRICTIVAS; c) UN POLINUCLEOTIDO QUE DIFIERE EN LA SECUENCIA DE CODONES DEBIDO A LA DEGENERACION DEL CODIGO GENETICO; QUE CODIFICA LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1, O UN FRAGMENTO ACTIVO DE LA MISMA; ii) A LA CELULA HOSPEDADORA QUE CONTIENE UN VECTOR DE EXPRESION O AL VECTOR QUE CONTIENE AL POLINUCLEOTIDO MENCIONADO; iii) A LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 O UN FRAGMENTO ACTIVO DE LA MISMA, TAL COMO LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 HUMANA, QUE ES CODIFICADA POR EL POLINUCLEOTIDO MENCIONADO; iV) UN ANTICUERPO MONOCLONAL QUE SE UNE ESPECIFICAMENTE A LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 HUMANA QUE IMPIDE LA ACTIVACION DEL COMPLEJO DEL RECEPTOR DE LA IL-1 MEDIENTE LA IL-1; V) EL PROCEDIMIENTO DE PREPARACION DE UNA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 QUE COMPRENDE: a) EXPRESION DE UN POLIPEPTIDO CODIFICADO POR UN ADN MENCIONADO EN UN HOSPEDERO ADECUADO; b) AISLAMIENTO DE DICHA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1; c) CONVERSION DE LA MISMA EN UN ANALOGO EN EL CUAL HAN SIDO MODIFICADOS GRUPOS SECUNDARIOS; Vi) PREPARACION DE UN ANTICUERPO DE LA PROTEINA ACCESORIA
PE1996000031A 1995-01-23 1996-01-15 Proteina accesoria del receptor de la interleucina 1 PE64396A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23

Publications (1)

Publication Number Publication Date
PE64396A1 true PE64396A1 (es) 1997-01-28

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000031A PE64396A1 (es) 1995-01-23 1996-01-15 Proteina accesoria del receptor de la interleucina 1

Country Status (19)

Country Link
EP (1) EP0808365A1 (es)
JP (1) JPH10512453A (es)
AR (1) AR003919A1 (es)
AU (1) AU4537096A (es)
BR (1) BR9606837A (es)
CA (1) CA2210724A1 (es)
CO (1) CO4480033A1 (es)
CZ (1) CZ208197A3 (es)
EA (1) EA199700265A1 (es)
FI (1) FI973089A0 (es)
HU (1) HUP9702458A2 (es)
IL (1) IL116796A0 (es)
MX (1) MX9705501A (es)
NO (1) NO973404L (es)
PE (1) PE64396A1 (es)
PL (1) PL321538A1 (es)
TR (1) TR199700652T1 (es)
WO (1) WO1996023067A1 (es)
ZA (1) ZA96333B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008969A1 (en) * 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
ATE406176T1 (de) 1996-12-06 2008-09-15 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0979282A1 (en) * 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Rat st38.2 chemokine
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
JP2001526892A (ja) 1997-12-23 2001-12-25 イミュネックス・コーポレーション Sigirrdnaおよびポリペプチド
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2002064630A2 (en) * 2000-10-31 2002-08-22 Immunex Corporation Il-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
JP2005509597A (ja) * 2001-08-07 2005-04-14 イミュネックス・コーポレーション 疾患の治療におけるインターロイキン−1受容体
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
EP1729810B1 (en) 2004-04-02 2018-08-15 Swedish Orphan Biovitrum AB (Publ) Methods of reducing aggregation of il-1ra
ES2395087T3 (es) * 2004-05-05 2013-02-08 Valorisation-Recherche, Société en Commandite Antagonistas del receptor de interleuquina-1, composiciones y métodos de tratamiento
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
AU2006264567A1 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US20110044894A1 (en) 2008-03-26 2011-02-24 Cellerant Therapeutics, Inc. Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
ES2714716T3 (es) 2011-01-19 2019-05-29 Cantargia Ab Anticuerpos anti-IL1RAP y su uso para el tratamiento de tumores sólidos
CN103608818B (zh) 2011-02-09 2017-12-08 纳特拉公司 非侵入性产前倍性识别装置
MX2013013627A (es) * 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
CN115505042A (zh) 2015-06-26 2022-12-23 赛诺菲生物技术公司 单克隆抗il-1racp抗体
BR112018070903A2 (pt) 2016-04-15 2019-01-29 Natera Inc métodos para detecção de câncer de pulmão
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
CN110945136A (zh) 2017-06-20 2020-03-31 威斯康星州立大学医学院 使用总无细胞dna评估移植并发症风险
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
WO2019200228A1 (en) 2018-04-14 2019-10-17 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
TW202021618A (zh) 2018-08-17 2020-06-16 美商23與我有限公司 抗il1rap抗體及其使用方法
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (en) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome
US20240224961A1 (en) * 2021-05-28 2024-07-11 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric il1rap
TW202428613A (zh) 2022-09-21 2024-07-16 法商賽諾菲生物技術公司 人源化抗il-1r3抗體及使用方法

Also Published As

Publication number Publication date
PL321538A1 (en) 1997-12-08
BR9606837A (pt) 1998-05-26
FI973089L (fi) 1997-07-22
HUP9702458A2 (hu) 1998-04-28
NO973404D0 (no) 1997-07-23
WO1996023067A1 (en) 1996-08-01
EP0808365A1 (en) 1997-11-26
ZA96333B (en) 1996-07-23
JPH10512453A (ja) 1998-12-02
CO4480033A1 (es) 1997-07-09
MX9705501A (es) 1997-10-31
FI973089A0 (fi) 1997-07-22
AR003919A1 (es) 1998-09-30
NO973404L (no) 1997-07-23
TR199700652T1 (xx) 1998-02-21
IL116796A0 (en) 1996-05-14
CA2210724A1 (en) 1996-08-01
AU4537096A (en) 1996-08-14
CZ208197A3 (en) 1997-11-12
EA199700265A1 (ru) 1998-04-30

Similar Documents

Publication Publication Date Title
PE64396A1 (es) Proteina accesoria del receptor de la interleucina 1
AR248044A1 (es) Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped.
IL86480A0 (en) Recombinant dna coding for human proapolipoprotein a-i,expression vectors containing it and cells transformed by said expression vector
ATE136908T1 (de) Peptide und antikörper, die die integrin- ligandbindung inhibieren
CA2096159A1 (en) Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates
IL86278A (en) Endowing cells with antibody specificity using chimeric t cell receptor
DK1015587T3 (da) DcR3 polypeptid, en TNFR-homolog
RU2014154067A (ru) Специфичная к ткани-мишени антигенсвязывающая молекула
TR199900267T2 (xx) GnRH-L�kotoksin kimeralar�.
ES2054601T1 (es) Proteina con actividad de tipo citoquina, adn recombinante codante para esta proteina, celulas y microorganismos transformados.
Porter The structure of the heavy chain of immunoglobulin and its relevance to the nature of the antibody-combining site. The Second CIBA Medal Lecture
NO940736L (no) DNA sekvenser som koder for gelonin polypeptid
BR9500271B1 (pt) seqüência de dna recombinante, vetor, células procarióticas e de fungo transformadas e proteìna com atividade sacarose-isomerase e com atividade de platinase e/ou trehalulase.
EA201001190A1 (ru) Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
NO975565L (no) Benstimulerende faktor
IL75553A (en) Dna sequence coding for a cholinesterase-like peptide, peptides produced by cells containing said dna and antibodies thereto
Sherman et al. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia
DK0667781T3 (da) Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier
ATE75754T1 (de) Monoklonale antikoerper gegen atriale, natriurethische peptide.
DE60031414D1 (de) Einkettige polypeptide enthaltend n-terminale troponin i fragmente und troponin c
DE69132874D1 (de) Für ein protein mit endochitinase-aktivität kodierendes rekombinantes gen
FR2829774B1 (fr) N-desoxyribosyltransferases de lactobacilles, sequences nucleotidiques correspondantes et leurs applications
NZ508812A (en) Peptides for the prevention or treatment of HIV
US6319890B1 (en) Inhibition of binding of complement Factor H

Legal Events

Date Code Title Description
FD Application declared void or lapsed